IMMUNEONCO-B (01541)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the Un...
- Open
- 3.755
- High
- 4.180
- Low
- 3.665
- Prev. Close
- 3.700
- Volume
- 1.99M
- Turnover
- 8.00M
- Avg Price
- 4.023
- Bid/Ask Ratio
- 65.85%
- Amplitude
- 13.92%
- 52wk High
- 16.800
- Volume Ratio
- 4.38
- Turnover Ratio
- 0.48%
IMMUNEONCO-B Analyst Rating
View moreForecast & Rating
Jul 10, 2026Price forecast
HK$6.2853.94%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 7 hours ago
ImmuneOnco doses first patient in Phase II trial of IMM2510-IMM27M combo for first-line advanced liver cancer
- PUBT · 1 day ago, 08:41 AM
ImmuneOnco FY26 interim revenue falls 33.2% to RMB 25.4 million; R&D expenses drop 7.9% to RMB 154.8 million
- Global Report · 2 days ago, 06:32 AM
Biopharma's Global Push and Boardroom Shakeups Across HK Equities
- PUBT · 2 days ago, 05:37 AM
ImmuneOnco says first PAH patient dosed in Phase Ib/IIa trial of IMC-003
- Global Report · 2 days ago, 04:20 AM
Forget the AI Hype: The Hong Kong Misfit Portfolio Testing Real Economy Durability
- PUBT · Aug 21 at 07:07 AM
ImmuneOnco wins FDA IND clearance for IMM0306 lupus Phase Ib/II trial
